The antiepileptic drugs diphenylhydantoin and phenobarbital were measured in serum by a new commercially available enzyme immunoassay procedure ("EMIT," Syva Corp.). The procedure requires <5 mm and no more than 50 l of serum per determination. It is simple; only four steps (pipetting and diluting with an automatic pipettor-dilutor) are required before spectrophotometry. Twenty replicate analyses of a serum containing phenobarbital and diphenylhydantoin gave results with a CV of 6.8% and 9.1%, respectively.
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Results attained in a large series of patients were compared with results by a gas/liquid chromatographic procedure. For phenobarbital r = 0.97, and for diphenyihydantoin r = 0.98. No false negatives or false positives were encountered.
The clinical value of determining the concentration of antiepileptic drugs in serum is well established and has recently been reviewed (1) . Such results are most effective if the clinician knows them at the time the patient is in the clinic. 
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Precision:
Within-day reproducibility of the gas chromatography was determined by the repeated 
